GLP-1 Receptor Agonists Show Emerging Potential for Cancer Prevention and Treatment in Obesity-Related Cancers

Obesity and type 2 diabetes are significant risk factors for various cancers, driving a critical need for effective prevention and treatment strategies. Current standard-of-care often addresses metabolic dysfunction and cancer separately, leaving a gap for therapies that can target both. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), well-established for improving glycemic control and promoting weight loss, are now being investigated for their potential anticancer properties. This interest stems from their ability to modulate key pathways like insulin signaling, inflammation, and cellular proliferation, which are central to tumorigenesis.

This review synthesized evidence from observational studies and secondary analyses regarding the role of GLP-1 RAs in the prevention and treatment of obesity-related cancer. It evaluated potential protective effects across various cancer types, including prostate, breast, pancreatic, gynecological, glioma, and oral squamous cell cancer. The authors also assessed safety concerns associated with GLP-1 RAs, specifically examining data on medullary thyroid carcinoma (MTC) and pancreatitis from both human and rodent studies. The analysis highlighted critical limitations in the current body of evidence.

Observational and secondary analyses suggest GLP-1 RAs may exert protective effects against several cancers, including prostate, breast, pancreatic, gynecological, glioma, and oral squamous cell cancer. These effects appear to operate through both weight-dependent and independent mechanisms, primarily by modulating crucial biological pathways such as insulin signaling, inflammation, and cellular proliferation. Initial concerns raised by rodent studies regarding medullary thyroid carcinoma have not been substantiated as a significant risk in human data. Similarly, early signals of pancreatitis and pancreatic cancer risk have been largely attenuated by subsequent rigorous analyses, indicating a more favorable safety profile than initially feared. Common side effects, such as gastrointestinal discomfort, are typically manageable and transient. > However, the review emphasizes that the absence of large-scale randomized controlled trials (RCTs) with cancer-specific endpoints remains a critical limitation, underscoring the preliminary nature of these findings.